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Abstract
This article is part of a series written for people responsible for making decisions about health policies and
programmes and for those who support these decision makers.
In this article, we address considerations about resource use and costs. The consequences of a
policy or programme option for resource use differ from other impacts (both in terms of benefits
and harms) in several ways. However, considerations of the consequences of options for resource
use are similar to considerations related to other impacts in that policymakers and their staff need
to identify important impacts on resource use, acquire and appraise the best available evidence
regarding those impacts, and ensure that appropriate monetary values have been applied. We
suggest four questions that can be considered when assessing resource use and the cost
consequences of an option. These are: 1. What are the most important impacts on resource use?
2. What evidence is there for important impacts on resource use? 3. How confident is it possible
to be in the evidence for impacts on resource use? 4. Have the impacts on resource use been valued
appropriately in terms of their true costs?
About STP
This article is part of a series written for people responsible for
making decisions about health policies and programmes and for
those who support these decision makers. The series is intended
to help such people ensure that their decisions are well-informed
by the best available research evidence. The SUPPORT tools
and the ways in which they can be used are described in more
detail in the Introduction to this series [1]. A glossary for the
entire series is attached to each article (see Additional File 1).
Links to Spanish, Portuguese, French and Chinese translations
of this series can be found on the SUPPORT website http://
www.support-collaboration.org. Feedback about how to
improve the tools in this series is welcome and should be sent to:
STP@nokc.no.
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Scenario
You work in the Ministry of Health and the Minister of Health
has asked you to brief her on the costs of options being consid-
ered as part of a healthcare reform programme.
Background
In this article, we present four questions that policymakers
and those who support them can ask when assessing the
costs of a policy or programme option. Such questions
could be applied, for instance, in the scenario outlined
above. Our focus is on finding and using evidence related
to resource use and the costs of a policy or programme
option, rather than on cost-effectiveness analysis or other
types of economic analysis.
Policymakers want to ensure that policies represent good
value for money, as do those affected by them. To do this
it is essential to consider the costs of options as well as
their health and other impacts. Option costs differ from
other impacts in a number of key ways [2]:
• Healthcare costs are typically shared. For most impacts
other than costs, it is usually clear who will be advantaged
and who will be disadvantaged, though this may not be
the case for all outcomes. An entire community will ben-
efit from a vaccination programme because of the herd
effect (the reduced transmission of the disease once most
community members are vaccinated). Similarly, in the
case of the widespread use of antibiotics to treat individ-
ual infections, downstream adverse consequences of drug
resistance may occur for the wider community. These are
exceptions for health outcomes. On the other hand,
healthcare costs are typically shared by the government,
private insurers, employers and patients. And within a
society, how costs are shared may differ still further
depending on patient age (e.g. whether they are under or
over 65) or circumstance (e.g. whether the patient is
receiving social assistance).
￿  Unit costs tend to vary widely across jurisdictions. For
instance, the cost per unit of drugs is largely unrelated to
the actual costs of production but is instead more closely
related to marketing decisions and national policies.
Thus, for example, most medicines under patent cost sub-
stantially more in the United States than in Canada [3].
Further, costs may vary widely even within jurisdictions.
Hospitals or health maintenance organisations may be
able to negotiate special arrangements with pharmaceuti-
cal companies for substantially lower prices than those
available to patients or other providers. Unit costs also
vary over time due to inflation, but may vary over time
due to factors relating to demand, too (e.g. when a drug is
indicated for use in an increased range of clinical applica-
tions), and supply (e.g. when a drug comes off patent).
￿ Resource use is likely to vary across jurisdictions. In addition
to unit costs, the amount of resources used may vary. This
is due to a range of factors, including professional prac-
tices (e.g. the extent to which a diagnostic test is requested
by clinicians for a particular health problem), service set-
tings (e.g. the balance between primary and secondary
care), levels of patient adherence, and reimbursement pol-
icies.
￿ Resource implications vary widely across jurisdictions. Even
when resource use remains constant, resource implica-
tions may vary widely across jurisdictions. A year's supply
of a very expensive drug may pay one nurse's salary in the
United States, six nurses' salaries in Eastern Europe, and
30 nurses' salaries in Africa. What one can buy with the
resources saved if one foregoes the purchase of a drug, vac-
cine or procedure - and the health benefits achievable
with those expenditures - may thus differ significantly [4].
￿ Stakeholders have different perspectives regarding the budg-
etary envelope in which they are considering resource implica-
tions. Individual patients may only be interested in their
out-of-pocket costs or may have varying views about risk
sharing or who should bear the costs of healthcare. Hos-
pital or district managers who are operating within fixed
budgets may consider the cost of an option relative to
other possible uses for the same money. Or they may
examine the opportunities available to them to shift
resources from one use to another. Similarly, a Minister of
Health may be interested primarily in healthcare costs and
the healthcare budget. Other policymakers, such as those
in a Ministry of Finance, may apply a broader perspective
and consider the overall government budget, including
non-healthcare expenditures and tax increases or reduc-
tions.
￿ Conflicting interests related to costs are common. For exam-
ple, the economic interests of health professionals or
industry executives (who typically want to earn as much as
possible) may often be in conflict with the interests of
society or governments (which typically want to get as
much as they can for as little as possible).
Despite these differences, cost considerations are similar
in many ways to considerations related to other conse-
quences. This is because policymakers and their staff also
need to identify important impacts on resource use, and
acquire and appraise the best available evidence regarding
those consequences to ensure that the resource conse-
quences have been valued appropriately [5-7]. Due to dif-
ferences between costs and other consequences, a
consideration of costs presents special challenges [2,8].
Figure 1 shows four steps that are necessary to identify and
incorporate evidence about resource use and costs when
considering policy and programme options.Health Research Policy and Systems 2009, 7(Suppl 1):S12 http://www.health-policy-systems.com/content/7/S1/S12
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Questions to consider
Table 1: Example: Identifying potentially important resource consequences for a national programme of outreach visits to improve 
prescribing for hypertension
Systematic reviews have found that educational outreach visits (i.e. personal visits to healthcare professionals in their own settings by trained 
outreach visitors) have relatively consistent and small, but potentially worthwhile, effects on prescribing [25]. In a randomised trial in Norway, 
these visits were found to increase the use of thiazides, in adherence with clinical practice guidelines, from 11% to 17% among patients with 
newly diagnosed hypertension [26]. To determine whether this improvement was worthwhile (in relation to the cost of a national outreach 
programme), the following uses of resources were considered [27]:
• Development of software (used to audit medical records and provide feedback to physicians)
• Training outreach visitors (pharmacists)
• Printed materials
• Travel for the pharmacists doing the outreach visits
• Pharmacists' time
• Administrative time (e.g. making appointments for the outreach visits)
• Physicians' time (for the outreach visits)
• Technical support
• Drug expenditure
• Patient visits
• Laboratory tests
Four steps necessary to identify and incorporate evidence of the costs of options Figure 1
Four steps necessary to identify and incorporate evidence of the costs of options.
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The following questions can be used to guide assessments
of the costs of potential options:
1. What are the most important impacts on resource use?
2. What evidence is there for important impacts on
resource use?
3. How confident is it possible to be in the evidence for
impacts on resource use?
Table 2: Examples of potentially important resource consequences*
1. Changes in use of healthcare resources
• Policy or programme delivery
- Human resources/time
- Consumable supplies
- Land, buildings, equipment
• Additional (or fewer) hospitalisations, outpatient visits or home visits
• Additional (or less) use of laboratory tests or examinations
• Paid transportation (e.g. emergency transportation)
2. Changes in use of non-healthcare resources
• Transportation to healthcare facilities
• Special diets
• Social services (e.g. housing, home assistance, occupational training)
• Home adaptation
• Crime (such as theft, fraud, violence, police investigation, court costs), for example, in relation to options targeted at drug or alcohol abuse
3. Changes in use of patient and informal caregiver time
• Outpatient visits
• Hospital admissions
• Time of family or other informal caregivers
4. Changes in productivity
• We suggest that changes in productivity and the intrinsic value of changes in health status should be captured in terms of the value or 
importance attached to health outcomes and should not be included as resource consequences
* Adapted from Luce and colleagues [10]
Table 3: Example: Finding evidence for resource consequences. The following data sources were used to estimate the differences in 
resource use between a programme of outreach visits (targeted at all general practitioners in Norway) and no programme (the status 
quo) [27]. The programme is described further in Table 1.
Resources Data sources
Development of software Invoices, estimates of time spent
Training of outreach visitors Estimate of time spent; invoices
Printed materials Invoice
Travel Record of travel days, estimate of travel distances
Pharmacists' time Record of number of visits and days spent on visits
Administrative time Records and estimates of time expenditure
Physicians' time Record of length of outreach visit and number of physicians present
Technical support Records of invoices
Drug expenditure Medical records
Patient visits Medical records
Laboratory tests Medical records
Because data were only collected for one year and from 139 practices (501 physicians, half of whom received outreach visits and half of whom did 
not) it was necessary to extrapolate the use of resources beyond one year and to the rest of the country.Health Research Policy and Systems 2009, 7(Suppl 1):S12 http://www.health-policy-systems.com/content/7/S1/S12
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4. Have the impacts on resource use been valued appro-
priately in terms of their true costs?
1. What are the most important impacts on resource use?
Health policies and programmes entail the use of
resources, particularly human resources such as time.
When considering which potential impacts on resource
use are important, policymakers should first focus on
resource use rather than costs (see Table 1, for example).
Examples of potentially important resource consequences
that should be considered include changes in the use of
healthcare resources, non-healthcare resources, and
patient and informal caregiver time (these and others
examples are outlined in Table 2).
When considering which impacts on resource use are
important it is essential to consider both the resources
used to implement the option (i.e. resource inputs such as
drugs, equipment and care) and subsequent resource use
arising from the impacts of the option on health or other
outcomes (e.g. increases or decreases in healthcare utilisa-
tion due to the impacts of the option). Incentives to
patients to improve adherence to tuberculosis treatment,
for example, require substantial resource inputs. These
may be offset by subsequent savings if there is a reduction
in failed treatment and less spread of the disease (and
therefore less subsequent resource use for retreatment and
the treatment of others who become infected).
Changes in the productivity of patients may also be
important. People with AIDS, for instance, may place a
high value on being able to work and earn money, but the
process of measuring and valuing actual changes in pro-
ductivity is controversial [9]. Like others [2,8,10], we sug-
gest that such changes in productivity should be
considered as components of the intrinsic value of
changes in health status, and should not be included as
resource consequences.
On the other hand, some outcomes such as hospitalisa-
tions or days in hospital can be considered as important
in their own right and also as a component of resource
use.
When deciding which resource consequences are poten-
tially important it is necessary to specify the viewpoint
from which recommendations are made. One option is to
adopt a societal perspective: this is a broad viewpoint that
includes all important healthcare and non-healthcare
resources [2]. This option has the advantage of ensuring
that the issue of who pays does not determine whether
resource use is included.
Policymakers may sometimes have a remit to make deci-
sions about the use of resources within a healthcare sys-
tem. In such instances, costs or savings outside of the
healthcare system would not be included. This exclusion
would not preclude a consideration of the impacts of an
option on issues such as social services or crime, in addi-
tion to health outcomes. But any costs or savings associ-
ated with those impacts would not be relevant to the
healthcare budget unless there was a transfer of funds (e.g.
from criminal justice to health).
It is also necessary to specify the time horizon for a policy
decision (i.e. the period of time for which resource use, as
well as health outcomes and other impacts, will be con-
sidered).
2. What evidence is there for important impacts on 
resource use?
Evidence must be found for each potentially important
resource consequence. Further, an estimate must be pro-
vided of the difference in resource use between imple-
menting the policy or programme on one hand, and the
comparator (typically the status quo) on the other (see
Table 3 for examples of resources and data sources used in
finding evidence of resource consequences). As with
health outcomes and other impacts, a comparison is
needed regardless of whether it is made implicitly or
explicitly. For instance, when considering the option of
scaling up the use of artemisinin combination therapy
(ACT) for uncomplicated falciparum malaria, increased
expenditures on ACT (and corresponding changes in the
use of other anti-malarials) must be compared to current
expenditures on ACT and other anti-malarials (the status
quo). Other resource consequences of scaling up the use
of ACT, such as training or providing incentives to com-
munity health workers to deliver ACT must also be com-
pared to the status quo (which may vary from setting to
setting). Similarly, any subsequent savings resulting from
scaling up the use of ACT (e.g. fewer hospitalisations)
must also be compared to the status quo. If two compet-
ing options for scaling up the use of ACT are being consid-
ered, it will be necessary to compare the resource
consequences of both of these to each other (either directly
or indirectly).
Systematic reviews, randomised trials and observational
studies may provide evidence of the impacts of options on
resource use. Such evidence can be published in, or sepa-
rately from, clinical studies or impact evaluations. The use
of resources in specific settings can be retrieved from
national or local databases, such as prescription databases
for drug use, and hospital databases for information
related to hospitalisations [11].
Evidence of resource use may also come from sources
other than those used to obtain evidence of health bene-
fits. This may be the case because:Health Research Policy and Systems 2009, 7(Suppl 1):S12 http://www.health-policy-systems.com/content/7/S1/S12
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￿ Trials or impact evaluations (and systematic reviews of
these) do not fully report resource use
￿ Trials and impact evaluations may not fully reflect the
circumstances - and thus the resource use - in the setting
where a policy decision must be made, and
￿ The relevant resource use may extend beyond the dura-
tion of the trial or impact evaluation
Evidence of resource use should be in natural units, such
as visits, hospitalisations or the number of doses of ACT.
There are two reasons for this. Firstly, when only total
costs are reported (i.e. the number of units of a resource
multiplied by the unit cost of the resource), resource use
cannot be separated from unit costs, which might vary
considerably between settings and over time. Secondly,
without information about resource use it is difficult to
make judgements about the validity and the applicability
of the evidence.
Unfortunately, studies sometimes report costs but do not
report the underlying levels of resource use. This was
apparent in an economic evaluation of magnesium sul-
phate for pre-eclampsia which reported the total cost, but
not the resource use for magnesium sulphate, or the
resources for administering magnesium sulphate and
other hospital resources [12]. Differences in costs could be
due to differences in underlying levels of resource use, dif-
ferences in unit costs, or both.
Often it is not possible to find evidence for components
of resource use that are important for policy decisions. A
guideline panel convened by WHO to develop recom-
mendations for the prevention of postpartum haemor-
rhage, for instance, found very limited evidence of
resource use for oral misoprostol compared to intramus-
cular oxytocin [8]. The panel considered hospitalisation,
personnel time, and drugs to be potentially important
resource consequences but did not find any evidence for
the first two types of resources. The resource consequences
of these two options for preventing postpartum haemor-
rhage were therefore very uncertain.
3. How confident is it possible to be in the evidence for 
impacts on resource use?
The quality of evidence for resource use must be assessed
for each important resource consequence (see Table 4).
This is because the quality of evidence may be better for
some consequences (e.g. drug use) than for other conse-
quences (e.g. personnel time). The criteria for assessing
the quality of evidence for resource use are largely the
same as those for health outcomes [2,7,8,13]. These
include: assessing the study design and other study limita-
tions (i.e. the risk of bias), the precision of the estimate,
the consistency of the results, the directness of the evi-
dence (see below), and the risk of publication bias. Fac-
tors that often lower the quality of resource evidence (i.e.
those that result in less confidence in estimates of resource
consequences) include:
￿ The unavailability of data due to resource use not having
been measured or reported, or reported only as cost esti-
mates (in other words, without the data upon which those
estimates were based)
￿ Weak (observational) study designs
￿ Indirectness due to uncertainty about the transferability
of resource evidence from one setting to another, and
￿ Indirectness due to inadequate follow-up periods. This
makes it necessary to extrapolate beyond the length of
available studies in order to estimate resource conse-
quences
Typically, when estimating the cost-effectiveness of a pol-
icy or programme, many assumptions must be made. Eco-
nomic models that are used to estimate cost-effectiveness
are valuable given that they can help to make such
assumptions explicit. They also allow for sensitivity anal-
yses that test how robust estimates of cost-effectiveness are
Table 4: Example: Assessing the quality of evidence for resource 
consequences. The quality of the evidence for the estimates of 
difference in resource use between a programme of outreach 
visits (targeted at all general practitioners in Norway) and no 
programme (the status quo) varied. (See also Tables 1 and 3.)
Resources Data sources
Development of software High quality
Training of outreach visitors High quality
Printed materials High quality
Travel Moderate quality*
Pharmacists' time Moderate quality*
Administrative time High quality
Physicians' time Moderate quality*
Technical support High quality
Drug expenditure Moderate to low quality†
Patient visits Moderate to low quality†
Laboratory test (potassium) Moderate to low quality†
* The evidence for travel, pharmacists' time and physician time was of 
moderate quality. This was because of uncertainty about the 
extrapolation of data from practices in the trial to the rest of the 
country
† The evidence for drug expenditures, patient visits and laboratory 
tests was of moderate to low quality. This was because of uncertainty 
about the extrapolation of data from the trial to the rest of the 
country and, in addition, because of extrapolation beyond one year 
(the duration of the trial) to estimate the resource consequences 
over several years for a programme targeted at all general 
practitioners in the countryHealth Research Policy and Systems 2009, 7(Suppl 1):S12 http://www.health-policy-systems.com/content/7/S1/S12
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in relation to those assumptions. It should be noted how-
ever, that the various checklists used to assess the quality
of economic analyses in the healthcare literature are not
constructed to assess the quality of the evidence upon
which the analyses were based [14]. Rather, these check-
lists tend to focus on the quality of the reporting.
Moreover, although published cost-effectiveness analyses
can be helpful, particularly for developing a model, they
are often of limited value to policymakers when they are
not from a policymaker's own setting. The assumptions
made and the unit costs that were used may not be trans-
ferable from the setting where the analysis was done to
one where a decision must be made. Also, as with any
research, cost-effectiveness analyses can be flawed. With-
out knowledge of the complete model it is difficult to
make informed judgements about either the quality of the
evidence or its applicability [2,8,15,16].
4. Have the impacts on resource use been valued 
appropriately in terms of their true costs?
Attaching appropriate monetary values to resource use
can help policymakers to value resource use consistently
and appropriately (see Table 5 for examples of relevant
data sources). In principle, these values should reflect
opportunity costs - that is, the benefits foregone by divert-
ing the resources from the next best alternative use [17].
Cost calculations based on reliable databases or data
sources in the same jurisdiction are the most reliable
Balancing the pros and cons of health policies and programmes, including resource consequences* Figure 2
Balancing the pros and cons of health policies and programmes, including resource consequences. Resource 
consequences (the savings or costs of a policy or programme compared to the status quo or other alternative) need to be con-
sidered along with health and other impacts when making judgements about the balance between the pros and cons of health 
policies and programmes
0Q_U^MNXQO[Z_Q]aQZOQ_
p4QMX`TNQZQRU`_
p;`TQ^NQZQRUOUMXUY\MO`_
p?MbUZS_
AZPQ_U^MNXQO[Z_Q]aQZOQ_
p-PbQ^_QTQMX`TQRRQO`_
p;`TQ^TM^YRaXUY\MO`_
p/[_`_
Table 5: Example: Attaching monetary values to resource consequences. The following data sources were used to estimate the 
monetary value of differences in resource use between a programme of outreach visits (targeted at all general practitioners in 
Norway) and no programme (the status quo) [27]. (See also Tables 1, 3 and 4.)
Variable Data sources for monetary values
Development of software Invoices, salary payments
Training of outreach visitors Salary payments
Printed materials Invoice
Travel Travel invoices
Pharmacists' time Salary payments
Administrative time Salary payments, standard estimates for overheads, office rental figures
Physicians' time Standard tariff for interdisciplinary meetings
Technical support Invoices
Drug expenditure "Felleskatalogen 2003" (a Norwegian list of drugs and prices)
Patient visits Standard tariff for consultation
Laboratory test (potassium) Standard tariffHealth Research Policy and Systems 2009, 7(Suppl 1):S12 http://www.health-policy-systems.com/content/7/S1/S12
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sources of data for unit costs [18]. Monetary valuations of
resource use should be made with data that are specific to
the context where a policy decision must be made using
transparent and locally relevant unit costs. If this is not
possible, purchasing power parity (PPP), exchange rates
and inflation factors could be used to assist interpretation
of monetary valuations from other settings or times [19].
In a study estimating the cost of cervical cancer screening
in five developing countries [20], for example, unit cost
data were derived from more than one year. Country-spe-
cific deflators were therefore used to adjust all costs to the
same price year. Further, to aid cross-country comparabil-
ity, PPP exchange rates were used to convert costs
expressed in local currency units to dollars. Both were
measured according to the relevant values in the price year
2000.
Discounting is used in economic evaluations to adjust for
social or individual preferences over the timing of costs
and health benefits. This means that less weight is given to
costs or benefits occurring further in the future than those
expected imminently. Recommended discount rates differ
between countries and are often varied in sensitivity anal-
yses.
When costs are presented, these should be reported using
the appropriate discount rate for the context where the
policy decision must be made. Data used to calculate the
discounted costs - including quantities of all resource
items, unit costs, and the discount rate - should be trans-
parent so that it is possible to assess the validity and appli-
cability or appropriateness of each component.
Conclusion
Policymakers and others are concerned with getting value
for money; in other words, that health policies and pro-
grammes are cost-effective (efficient). Evidence of
resource use and costs is needed to inform judgements
about cost-effectiveness. We discuss making judgements
about the balance between the pros and cons (including
savings and costs) of policies and programmes (as illus-
trated in Figure 2) in a later article in this series [21].
Evidence of resource use and costs is also needed to
inform judgements about equity [22]. In addition to con-
sidering the overall costs (and cost-effectiveness) of poli-
cies and programmes, policymakers need to consider who
will bear particular costs and the impact that this will have
on inequities.
In terms of both efficiency and equity it is important to
ensure that all potentially important resource conse-
quences are identified. It is also essential that the best
available evidence is used, and that important uncertain-
ties about resource (and other) consequences are
acknowledged and addressed [23,24].
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sioD=&SearchID=&E=0&D=0&H=0&SearchFor= - NHS
EED contains 24,000 abstracts of health economics
papers including over 7,000 quality-assessed economic
evaluations. The database aims to assist decision makers
by systematically identifying and describing economic
evaluations, appraising their quality, and highlighting
their relative strengths and weaknesses.
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